EORTC has been involved in a number of large practice-changing clinical trials in the field of Soft Tissue and Bone, leading to the registration of drugs to treat sarcomas including gastrointestinal stromal tumors (GIST).
PRACTICE CHANGING RESEARCH
Soft Tissue & Bone
EORTC 62001 – Dose finding and phase II study of STI 571 in advanced soft tissue sarcoma.
This EORTC trial is one of the landmark studies of the organization, whereby the EORTC Soft Tissue and Bone Sarcoma Group (STBG) helped develop imatinib as a treatment for metastatic gastrointestinal stromal tumours (GISTs) by identifying safe dosage and studying early activity of the drug. This remains the reference treatment for this disease.
EORTC 62005 – Phase III randomized, intergroup, international trial assessing the clinical activity of STI-571 at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) expressing the KIT receptor tyrosine kinase (CD117).
In 2004, EORTC published results of an additional clinical trial, where it optimized the dosage for the timatinub treatment of advanced or metastatic gastrointestinal stromal tumour (GIST).